(MIRD Synopsis for Radiopharmaceutical Therapies With Lu-177)
In 2023, the MIRD committee generated a poster outlining the major dosimetry concepts required to support current FDA approved lutetium (177LU) -based therapies: 177Lu-DOTATATE and 177Lu-PSMA. The poster was presented at the 2023 annual Society of Nuclear Medicine and Molecular Imaging conference, and is available for download here:
Download Hi Res PDF (free)
The ideal realization of routine dosimetry includes quality and standardized workflows that can be integrated with patient management standards of care. At this stage, most workflows are built locally, based on local expertise to ensure optimal dosimetry accuracy and dependability. The aim, of this educational work is to make available the key points in 177Lu dosimetry, to “de-mystify” the different steps of the dosimetry workflow, highlighting the advantages and limitations of different methods, in a simple yet complete “MIRD Synopsis for Radiopharmaceutical Therapies with 177Lu”.
This synopsis is presented as a single poster that will be freely accessible and can be placed in nuclear medicine departments and research centers. It emphasizes the importance of dosimetry for personalized medicine and educates the nuclear medicine community on the important factors and steps for performing quality dosimetry in a clinical setting.
Reference: Uribe et. al., “MIRD Synopsis for Radiopharmaceutical Therapies with Lu-177”, SNMMI annual conference, 2023